Does orlistat fail to alter postprandial plasma lipid excursions or plasma lipases in normal-weight male volunteers?
The results indicate that the oral administration of orlistat (120 mg t. i.d.) does not significantly alter plasma triglycerides or lipoproteins, and that the inhibitory effect of orlistat on lipases is limited to the gastrointestinal tract and is not manifested systemically.
Metabolic syndrome may account for the differences in postprandial lipemia that have been attributed to age. In our study, there were no significant differences in postprandial lipemia between a young population (mean age 22.6 years) and a healthy people >65 years one (67.2 years) without metabolic syndrome.